A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via both Notch2 and Notch3, in adult patients with advanced ma...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Smith, David C., Chugh, Rashmi, Patnaik, Amita, Papadopoulos, Kyriakos P., Wang, Min, Kapoun, Ann M., Xu, Lu, Dupont, Jakob, Stagg, Robert J., Tolcher, Anthony
Format: Artigo
Langue:Inglês
Publié: Springer US 2018
Sujets:
Phase I Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647865/
https://ncbi.nlm.nih.gov/pubmed/30591982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0714-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires